Goldline Pharmaceutical Ltd.
GOLDLINESME
Ask IPO
Overview
Goldline Pharmaceutical Limited markets pharmaceutical products in India under the Goldline brand through a third-party manufacturing model. Goldline Pharmaceutical Limited operates across five product segments—Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife and Goldline Wellness—covering therapies such as general medicine, cardio-diabetic care, pediatrics, critical care and supportive oncology care. The company works with 15 contract manufacturers and 8 distributors, sells largely through wholesale channels across multiple Indian states, and also provides material supply and procurement support to hospitals and healthcare partners.
Opening Date
May 12, 2026
Closing Date
May 14, 2026
Listing Date
May 19, 2026
IPO Type
SME
IPO Status
Closed
Issue Size
11.61 Cr
Fresh Issue
11.61 Cr
Offer for Sale
0 Cr
Price Band
₹41 - ₹43
Lot Size
3000
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
IPO Objective
The main objectives of the issue are to strengthen the company’s balance sheet and support its ongoing business requirements.
- •
Repayment or prepayment of all or a portion of certain outstanding borrowings availed by the company, including working capital and business loans from multiple lenders, in order to reduce overall indebtedness, lower finance costs, improve leverage ratios and free internal accruals for future business growth.
- •
Funding general corporate purposes, which may include supporting routine operational needs, strengthening working capital flexibility, meeting business development requirements, and enhancing the company’s overall financial and corporate capabilities.
- •
Achieving the benefits of listing on the stock exchange, including improved brand visibility, enhanced credibility with stakeholders, creation of a public market for the equity shares and liquidity for existing shareholders.
Key Performance Indicator
P/E Ratio
10.47
EPS
4.11
ROE
21.02%
ROCE
24.22%
RONW
17.99%
Debt to Equity Ratio
—
PAT Margin
10.38%
EBITDA Margin
19.41%
P/B
3.47
SWOT Analysis
Strengths
- •
Diversified branded product portfolio across five therapeutic segments including general medicine, cardio-diabetic, pediatric, critical care and wellness categories.
- •
Asset-light third-party manufacturing model with 15 contract manufacturers enables focus on marketing, distribution and brand building.
- •
Established domestic distribution presence with 8 distributors and strong sales concentration in key states such as Maharashtra and Madhya Pradesh.
- •
Improving financial performance with revenue growth and stronger profitability over FY2023 to FY2025, supported by better margins and return ratios.
Weaknesses
- •
Business is fully dependent on third-party manufacturers, exposing operations to quality, capacity, delivery and compliance risks.
- •
High customer and distributor concentration, with top customers contributing a large share of revenue and only 8 distributors in the network.
- •
Operations are geographically concentrated in a limited number of Indian states, increasing exposure to regional demand fluctuations.
- •
The company does not undertake in-house R&D or formulation development, limiting control over product innovation and technical capabilities.
Opportunities
- •
Growing Indian pharmaceutical market and rising demand for chronic therapies such as cardiovascular and anti-diabetic treatments can support portfolio expansion.
- •
Expansion into additional geographies, rural markets and new product categories can broaden the company’s domestic reach.
- •
Increasing demand for supportive care, specialty therapies and hospital supply solutions can create cross-selling opportunities beyond core branded products.
- •
Reduction of debt through IPO proceeds can improve financial flexibility and allow more internal accruals to be deployed toward growth initiatives.
Threats
- •
Stringent pharmaceutical regulations, licensing requirements and quality compliance obligations could disrupt operations if not met by the company or its manufacturers.
- •
Intense competition from other pharmaceutical marketers and larger companies may pressure pricing, margins and brand positioning.
- •
Supply chain disruptions, logistics failures or transit losses could affect product availability and timely delivery to distributors.
- •
Outstanding litigations, compliance lapses in statutory filings or tax matters, if decided adversely, may impact financial condition and reputation.
Subscription Rate
Frequently Asked Questions about Goldline Pharmaceutical Ltd.
Goldline Pharmaceutical Limited markets pharmaceutical products in India under the Goldline brand through a third-party manufacturing model. Goldline Pharmaceutical Limited operates across five product segments—Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife and Goldline Wellness—covering therapies such as general medicine, cardio-diabetic care, pediatrics, critical care and supportive oncology care. The company works with 15 contract manufacturers and 8 distributors, sells largely through wholesale channels across multiple Indian states, and also provides material supply and procurement support to hospitals and healthcare partners.
The Goldline Pharmaceutical Ltd. IPO is scheduled to open for subscription on May 12, 2026 and close on May 14, 2026. Investors can apply for shares during this period through eligible platforms.
The price band for the Goldline Pharmaceutical Ltd. IPO is ₹41 to ₹43. Investors can place bids within this range once the issue opens.
The minimum lot size for the Goldline Pharmaceutical Ltd. IPO is 3000 shares. The minimum investment amount ₹1,29,000.
The total issue size of the Goldline Pharmaceutical Ltd. IPO is approximately ₹11.61. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Goldline Pharmaceutical Ltd. IPO has been subscribed data will be available once the issue opens. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Goldline Pharmaceutical Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Goldline Pharmaceutical Ltd. are expected to list on stock exchanges on May 19, 2026, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Goldline Pharmaceutical Ltd. IPO are proposed to be used for The main objectives of the issue are to strengthen the company’s balance sheet and support its ongoing business requirements., Repayment or prepayment of all or a portion of certain outstanding borrowings availed by the company, including working capital and business loans from multiple lenders, in order to reduce overall indebtedness, lower finance costs, improve leverage ratios and free internal accruals for future business growth., Funding general corporate purposes, which may include supporting routine operational needs, strengthening working capital flexibility, meeting business development requirements, and enhancing the company’s overall financial and corporate capabilities., Achieving the benefits of listing on the stock exchange, including improved brand visibility, enhanced credibility with stakeholders, creation of a public market for the equity shares and liquidity for existing shareholders.
Before applying for the Goldline Pharmaceutical Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
